PTAB statistics

PTAB Trial Statistics as of January 1, 2015

As of January 1, 2015, USPTO records show 2,585 AIA trial petitions filed since September 16, 2012 (2,299 IPR, 277 CBM, 3 PGR, 6 derivation). The Board had instituted trial on 1,128 petitions and denied 542 (67.5% instituted) and had issued 245 final written decisions. In fiscal year 2015 to that date, 504 petitions were filed.

Key Facts

As of
January 1, 2015
Fiscal year
FY2015
Petitions filed (cumulative)
2,585
Institution rate (cumulative)
67.5%
Petitions filed (FY2015 to date)
504
Data retrieved
October 31, 2026
On this page
  1. Cumulative Figures as of January 1, 2015
  2. Fiscal Year 2015 to Date
  3. Change Since December 18, 2014
  4. Trial Types Covered
  5. How These Figures Were Compiled
  6. Related Statistics

This page gives Patent Trial and Appeal Board trial figures as of January 1, 2015, which falls in fiscal year 2015 (October 1, 2014 to September 30, 2015). The cumulative figures run from September 16, 2012, when AIA trials began. The full year is covered on the FY2015 statistics page.

Cumulative Figures as of January 1, 2015

Events from September 16, 2012 to January 1, 2015, by trial type:

MeasureIPRPGRCBMDERTotal
Petitions filed2,299327762,585
Institution decisions: instituted1,003012501,128
Institution decisions: denied4771613542
Institution rate (by petition)67.8%0.0%67.2%0.0%67.5%
Final written decisions2150300245
Terminations without a final written decisionCount
Settlements215
Adverse judgment0
Dismissed0
Other terminations8

Fiscal Year 2015 to Date

Events from October 1, 2014 to January 1, 2015:

MeasureIPRPGRCBMDERTotal
Petitions filed4581441504
Institution decisions: instituted2640180282
Institution decisions: denied124150130
Institution rate (by petition)68.0%0.0%78.3%—68.4%
Final written decisions65013078
Terminations without a final written decisionCount
Settlements71
Adverse judgment0
Dismissed0
Other terminations0

Change Since December 18, 2014

Between the previous dated page (December 18, 2014) and January 1, 2015, 89 petitions were filed, 24 trials were instituted, 16 petitions were denied institution and 10 final written decisions issued. The cumulative institution rate moved from 67.7% to 67.5%.

Trial Types Covered

2,299 of the 2,585 petitions (88.9%) were for inter partes review, which challenges patent claims on prior-art grounds under 35 U.S.C. chapter 31. The remainder were for covered business method review (277), post-grant review under chapter 32 (3) and derivation proceedings (6). Institution standards differ by proceeding; see the threshold standards.

How These Figures Were Compiled

The figures are counted from USPTO Open Data Portal records retrieved on October 31, 2026, keeping only events dated on or before January 1, 2015: a petition by its filing date, an institution decision by its decision date, and a final written decision or termination by its date. They are a reconstruction from the current records, not the USPTO’s report of that date, and may differ from statistics the USPTO published at the time. Final written decision outcomes are not reported because the records state them for too few decisions. The methodology gives the counting rules in full.

Frequently Asked Questions

How many AIA trial petitions had been filed as of January 1, 2015?

USPTO records show 2,585 petitions filed from September 16, 2012 to January 1, 2015: 2,299 IPR, 277 CBM, 3 PGR and 6 derivation.

What was the PTAB institution rate as of January 1, 2015?

Cumulatively, 67.5% by petition: 1,128 instituted and 542 denied. In FY2015 to that date the rate was 68.4%.

Primary Sources

  1. USPTO Open Data Portal (PTAB trial proceedings and decisions data)
  2. USPTO Patent Trial and Appeal Board statistics
  3. 35 U.S.C. chapter 31 (inter partes review)
  4. 35 U.S.C. chapter 32 (post-grant review)
  5. 37 C.F.R. Part 42 (trial practice before the PTAB)

Educational information; not legal advice. Statutes, rules and USPTO practice change. Confirm against the primary sources and consult a registered patent practitioner before acting. Disclaimer.